MedMira Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MMIRF research report →
Companywww.medmira.com
MedMira Inc. , a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis.
- CEO
- Hermes Chan
- IPO
- 2009
- Employees
- 52
- HQ
- Halifax, NS, CA
Price Chart
Valuation
- Market Cap
- $8.49M
- P/E
- -11.98
- P/S
- 223.37
- P/B
- -1.74
- EV/EBITDA
- -26.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -823.96%
- Op Margin
- -1178.81%
- Net Margin
- -1853.95%
- ROE
- 15.28%
- ROIC
- 33.44%
Growth & Income
- Revenue
- $240.51K · -41.70%
- Net Income
- $-4,524,407 · -36.02%
- EPS
- $-0.00 · 2.08%
- Op Income
- $-3,589,747
- FCF YoY
- 14.35%
Performance & Tape
- 52W High
- $0.95
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.04
- Beta
- 0.75
- Avg Volume
- 1.74K
Get TickerSpark's AI analysis on MMIRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MMIRF Coverage
We haven't published any research on MMIRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MMIRF Report →